Skip to content
Lower risk Drug recall · FDA · Published November 22, 2022

Fresenius Kabi Sensorcaine Injection Recall: Subpotent Epinephrine Risk

Fresenius Kabi recalls Sensorcaine injections with subpotent epinephrine due to testing below defined limits. Affected batches expire April 2024. Stop using immediately if you have the recalled product.

🇺🇸 FDA recall #D-0128-2023DrugFresenius Kabi ›
Take action

Contact the company

Recalling firmFresenius Kabi USA, LLC3 Corporate Dr · Lake Zurich, IL 60047-8930
✎ GovInfoNow plain-language explainer

Fresenius Kabi is recalling Sensorcaine injections that contain less epinephrine than required. This could lead to ineffective pain management during procedures if used as intended. The recall affects specific batches of the product that expire in April 2024. Read more at govinfonow.com/recall/34216-fresenius-kabi-sensorcaine-injection-recall-subpotent-epinephrine-risk.

Source Summary by GovInfoNow · govinfonow.com/recall/34216-fresenius-kabi-sensorcaine-injection-recall-subpotent-epinephrine-risk · Updated August 17, 2026 · FDA enforcement record: FDA #D-0128-2023

Cite this page

“Fresenius Kabi Sensorcaine Injection Recall: Subpotent Epinephrine Risk.” GovInfoNow, updated August 17, 2026. https://govinfonow.com/recall/34216-fresenius-kabi-sensorcaine-injection-recall-subpotent-epinephrine-risk. Based on FDA recall #D-0128-2023 (https://api.fda.gov/drug/enforcement.json?search=recall_number:%22D-0128-2023%22&limit=1).

The FDA announced on November 22, 2022, that Fresenius Kabi USA, LLC voluntarily recalled Sensorcaine (Bupivacaine HCl and Epinephrine Injection, USP) with Epinephrine 1:200,000. The product is subpotent because testing results fell below the defined limit for the epinephrine portion.

How to tell if you have it

  • Brand: Fresenius Kabi
  • Product: Sensorcaine (Bupivacaine HCl and Epinephrine Injection, USP) with Epinephrine 1:200,000 (as bitartrate), 0.5%, 250 mg per 50 mL
  • Packaging: 50 mL Multiple Dose Vial (NDC 63323-463-01), packaged in 25 Multiple Dose Vials per tray (NDC 63323-463-57)
  • Batch #: 6128399, 6128400, 6128401
  • Expiration: 04/2024
  • Units affected: 40,025 vials

The hazard

The recall is due to the product being a subpotent drug. Testing results were below the defined limit for the epinephrine portion of Sensorcaine.

Context

GovInfoNow's records show Fresenius Kabi USA, LLC has 65 other recalls on record since September 27, 2012. Other recent recalls of similar products include Fresenius Kabi Tyenne Injection Recall (August 10, 2026), Fresen: Morphine Syringes May Have Wrong Labeling (August 4, 2026), and Fresenius Kabi Xylocaine 1% Injection Recall (July 16, 2026). Other recent recalls of similar products include Fresenius Kabi Ketamine HCl Injection Recall (February 5, 2026), Fresenius Kabi Thiamine HCl Injection Recall (February 5, 2026), and Fresenius Kabi acyclovir injection recall (February 5, 2026).

How to tell if you have this one

Check for the product name 'Sensorcaine' with the specific batch numbers 6128399, 6128400, or 6128401. The product expires April 2024 and comes in 50 mL vials.

  • Brand
    Fresenius Kabi
  • Category
    Drug
FDA recall event · 3 products

All 3 products in this recall

FDA lists each product line separately under one recall event. Check your product description, lot or code numbers against each row. Every row shares the hazard and remedy on this page.

  • Classification
    Class II
  • Status
    Terminated
  • Distribution
    Nationwide in the USA
  • NDC
    63323-472-03, 63323-472-17, 63323-472-01, 63323-472-37, 63323-463-01, 63323-463-57, 63323-461-01, 63323-461-57, 63323-468-02, 63323-468-37, 63323-468-01, 63323-468-17
Recall numberProduct, codes & lotsQuantity
D-0127-2023Sensorcaine (Bupivacaine HCl and Epinephrine Injection, USP) with Epinephrine 1:200,000 (as bitartrate), 0.25%, 125 mg per 50 mL (2.5 mg per mL), 50 mL Multiple Dose Vial (NDC 63323-461-01), packaged in 25 Multiple Dose Vials per tray (NDC 63323-461-57), Rx only, Fresenius Kabi, Lake Zurich, IL 60047.; Batch #: 6128061, exp 03/2024; 6128663, 6128664, exp 05/202440,375 vials
D-0128-2023Sensorcaine (Bupivacaine HCl and Epinephrine Injection, USP) with Epinephrine 1:200,000 (as bitartrate), 0.5%, 250 mg per 50 mL (5 mg per mL), 50 mL Multiple Dose Vial (NDC 63323-463-01), packaged in 25 Multiple Dose Vials per tray (NDC 63323-463-57), Rx only, Fresenius Kabi, Lake Zurich, IL 60047.; Batch #: 6128399, 6128400, 6128401, exp 04/202440,025 vials
D-0129-2023Sensorcaine-MPF (Bupivacaine HCl and Epinephrine Injection, USP) with Epinephrine 1:200,000 (as bitartrate), 0.25%, 25 mg per 10 mL (2.5 mg per mL), 10 mL Single Dose Vial (NDC 63323-468-01), packaged in 25 Single Dose Vials per tray (NDC 63323-468-17), Rx only, Fresenius Kabi, Lake Zurich, IL 60047.; Batch #: 6128800, exp 12/202331,600 vials
Based on the official FDA remedy

What to do — step by step

  1. Check Product Details

    Identify the batch number on the vial (6128399, 6128400, or 6128401) to confirm if it is affected.

  2. Contact Healthcare Provider

    If you have the recalled product, inform your healthcare provider immediately to discuss alternative options.

Where it went and when

Where it was distributed

Distributed nationwide.

Alaska: yesAKMaine: yesMEVermont: yesVTNew Hampshire: yesNHWashington: yesWAIdaho: yesIDMontana: yesMTNorth Dakota: yesNDMinnesota: yesMNIllinois: yesILWisconsin: yesWIMichigan: yesMINew York: yesNYRhode Island: yesRIMassachusetts: yesMAOregon: yesORNevada: yesNVWyoming: yesWYSouth Dakota: yesSDIowa: yesIAIndiana: yesINOhio: yesOHPennsylvania: yesPANew Jersey: yesNJConnecticut: yesCTCalifornia: yesCAUtah: yesUTColorado: yesCONebraska: yesNEMissouri: yesMOKentucky: yesKYWest Virginia: yesWVVirginia: yesVAMaryland: yesMDDelaware: yesDEArizona: yesAZNew Mexico: yesNMKansas: yesKSArkansas: yesARTennessee: yesTNNorth Carolina: yesNCSouth Carolina: yesSCDistrict of Columbia: yesDCOklahoma: yesOKLouisiana: yesLAMississippi: yesMSAlabama: yesALGeorgia: yesGAHawaii: yesHITexas: yesTXFlorida: yesFL

FDA distribution: “Nationwide in the USA” States read from FDA’s own wording; “not listed” means the notice does not name it.

Distributed nationwide.

Recall timeline

FDA terminated this recall 11 months after the firm started it.

1. Firm started the recall: Nov 22, 202212. FDA classified it Class II: Jan 13, 202323. Published in FDA’s Enforcement Report: Jan 25, 202334. FDA terminated the recall: Oct 23, 2023420222023
  1. Firm started the recall
  2. FDA classified it Class II
  3. Published in FDA’s Enforcement Report
  4. FDA terminated the recall

Dates from the agency record only; steps without a date are left out.

✎ GovInfoNow

Questions people ask

What should I do if I have the recalled product?

Contact your healthcare provider to discuss alternatives and ensure safe use of the product.

Similar recalls

Latest drug recalls

Keep exploring

Where this comes from

The facts (hazard, remedy, dates, manufacturer) are pulled from the official FDA recall record. The plain-language summary and step-by-step checklist are written by GovInfoNow to make the official notice easier to act on — they don’t replace it.

  • Official source: FDA Recall #D-0128-2023 (November 22, 2022) — FDA publishes no per-recall page; this is the official machine-readable enforcement record. Search FDA recalls for D-0128-2023 to see it in context.
  • Plain-language summary written by qwen3:4b on August 17, 2026, from the official record above. Not reviewed by a person — if it conflicts with the FDA notice, the notice is correct. Report an error on this page.
  • GovInfoNow is an independent service and is not a government agency. We republish official FDA recall data; we don’t issue, amend or administer recalls.
GovInfoNow is an independent guide. We are not FDA or any government agency. Always confirm details with the official recall.Data: CPSC · FDA · NHTSA · USDA